Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
Here's Why Astrazeneca (AZN) is a Strong Value Stock
10:42am, Monday, 14'th Jul 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
AstraZeneca shares show signs of life after successful trials of hypertension drug
08:50am, Monday, 14'th Jul 2025
Baxdostat trials showed immense promise for huge available market.
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically mean
AstraZeneca drug lowers high BP in late-stage study; shares rise
03:29am, Monday, 14'th Jul 2025
AstraZeneca 's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of people whose condition was hard to control or treat, the Anglo-Swedish drugmake
AstraZeneca and GSK slide on Trump threats but analysts see positive catalysts ahead
08:01am, Friday, 11'th Jul 2025
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) were both down over 1% on Friday, but the shares are worth buying, analysts at Shore Capital said. Blue-chip shares across Lon
Trumps 200% tariffs. Here's what it means for UK pharma investors
09:47am, Thursday, 10'th Jul 2025
UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive
AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
09:46am, Wednesday, 09'th Jul 2025
If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN) should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipel
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
11:46am, Tuesday, 08'th Jul 2025
AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.
AstraZeneca: Just What The Doctor Ordered
07:00am, Tuesday, 08'th Jul 2025
AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
09:36am, Friday, 04'th Jul 2025
AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
05:10am, Friday, 04'th Jul 2025
Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus
AstraZeneca wins EU approval for Imfinzi in early bladder cancer treatment
03:15am, Friday, 04'th Jul 2025
AstraZeneca PLC's (LSE:AZN) cancer drug Imfinzi has been approved in the European Union for use before and after surgery in patients with muscle-invasive bladder cancer, marking a significant step for
Why AstraZeneca Stock Got Thumped on Thursday
06:26pm, Thursday, 03'rd Jul 2025
AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the
Report: Summit in talks for $15 billion partnership with AstraZeneca
11:38am, Thursday, 03'rd Jul 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
Summit considers up to $15 billion partnership with AstraZeneca, Bloomberg News reports
10:39am, Thursday, 03'rd Jul 2025
Summit Therapeutics is considering an up to $15 billion partnership with AstraZeneca , Bloomberg News reported on Thursday, citing people familiar with the matter.
